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Introduction {#sec1}
============

Breast cancer (BC) is the leading cause of cancer death in women worldwide ([@bib33], [@bib34]), particularly in developed countries. Genetic factors, such as mutations of tumor suppressor genes BRCA1 and BRCA2; endocrine factors (such as estrogen exposure); as well as environmental and dietary factors may be involved in the onset of this disease. Several studies of gene expression profile have been performed to characterize BCs in different molecular subtypes, which may have a prognostic value ([@bib43]). An important classification can be made on the basis of specific receptor expression. Indeed, BCs are divided into hormone receptor (HR)-negative (HR−) and HR-positive (HR+) tumors. The latter group includes estrogen receptor (ER)-positive (ER+), progesterone receptor (PR)-positive (PR+), and human epidermal growth factor receptor 2 (HER2)-positive (HER2+) tumors, whereas HR− tumors include the so-called triple-negative breast cancers (TNBCs), which lack the expression of the three receptor types ([@bib19]). Although the survival rate at 5 years for treated patients with early-stage BC is extremely high, some subgroups of patients with advanced-stage BC may have recurrence within 10 years of treatment. The recurrence rate for HR+ tumors appears to be lower (recurrence rate is 8%) compared with that of the subtypes overexpressing HER2 or that have a triple-negative phenotype (recurrence rate is 15%--20%) ([@bib15], [@bib27], [@bib28]).

The selective ER modulator (SERM) tamoxifen and aromatase inhibitors (anastrazole, letrozole) are used for the treatment of tumors expressing steroid HRs, while trastuzumab (Herceptin), a monoclonal antibody that targets HER2, is used for the treatment of HER2+ tumors. TNBCs are particularly dangerous, because they are associated with an unfavorable prognosis ([@bib2], [@bib5], [@bib15]) and because patients with TNBC derive no benefit from molecularly targeted regimens employing endocrine-based therapy or trastuzumab ([@bib19]). Classical chemotherapy aims to block cell proliferation, which, however, does not discriminate cancer cells from rapidly dividing normal cells within the organism. Therefore, new therapeutic approaches resulting from the discovery of new compounds with antitumor activity against TNBCs are still highly desirable.

In this work, we report an unprecedented catalytic double cyclization process leading to a new class of bicyclic heterocycles (dihydrofurofuranone derivatives) with significant antitumor activity *in vitro* against BC cell lines, both HR+ (MCF-7) and TNBCs (MDA-MB-231 and MDAMB-468), while exhibiting practically no effects on normal MCF-10A (human mammary epithelial) and 3T3-L1 (murine fibroblasts) cells. These new compounds have therefore the potential to expand the therapeutic options against BC, in particular against its most aggressive forms (TNBCs).

Results and Discussion {#sec2}
======================

Palladium-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,2-diols Leading to Dihydrofurofuranone Derivatives {#sec2.1}
----------------------------------------------------------------------------------------------------------------------------

Catalytic cyclization processes have recently attracted great interest in the chemistry scientific community owing to the possibility to synthesize in one step high-value-added molecules starting from simple building blocks, by their ordered sequential activation by the catalytic center ([@bib1], [@bib7], [@bib14], [@bib21], [@bib36], [@bib37], [@bib42], [@bib53]). Among the raw starting materials, carbon monoxide represents a simple and largely available C-1 unit, and its catalytic activation may allow to directly introduce a carbonyl functional group into an organic substrate in a highly atom-economical and efficient manner. In fact, carbonylation reactions are currently known to play a major role in the direct synthesis of carbonyl compounds both in industry and in the production of fine chemicals ([@bib3], [@bib9], [@bib10], [@bib12], [@bib13], [@bib17], [@bib20], [@bib23], [@bib29], [@bib30], [@bib32], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51]).

In this work, we have developed an unprecedented carbonylative oxidative double cyclization process, which allows synthesizing bioactive, high-value-added bicyclic heterocycles (dihydrofurofuranone derivatives **2**) starting from readily available 4-yne-1,3-diols **1**; CO; and O~2~ ([Scheme 1](#sch1){ref-type="fig"}). In this reaction, the alkynediol, carbon monoxide, and oxygen are sequentially activated through the catalytic action of a very simple system (consisting of PdI~2~ in conjunction with an excess of KI) ([@bib11], [@bib24], [@bib25], [@bib26], [@bib38], [@bib39], [@bib40], [@bib41]), with the formation of two cycles and three new bonds (O-C, C-C, and C-O) in one single operation and in ordered sequence. It should be noted that, although an analogous process was reported for 4-ene-1,2-diols under different reaction conditions ([@bib18]), no previous example exists in the literature for the direct carbonylative double cyclization of 4-yne-1,3-diols leading to dihydrofurofuranones.Scheme 1PdI~2~-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,3-diols Leading to Dihydrofurofuranones

We started our investigation by studying the reaction between 3-methylnon-4-yne-1,3-diol **1a** and carbon monoxide using 2 mol % PdI~2~ and 10 mol % KI, under 40 atm of a 4:1 mixture of CO and air in MeOH as the solvent (0.05 mmol of **1a** per mL of MeOH) at 100°C. After 15 hr reaction time, 3-butyl-6*a*-methyl-6,6*a*-dihydrofuro\[3,2-*b*\]furan-2(5*H*)-one **2a** was isolated in 30% yield following chromatographic purification (unidentified heavy by-products accounted for substrate total conversion). The yield of **2a** did not improve by changing the operative reaction conditions (data not shown); however, its formation confirmed the possibility to realize a previously unreported carbonylative double cyclization process starting from a 4-yne-1,3-diol in one step under catalytic conditions. The result was noteworthy, considering the different possible competitive pathways that could have been followed under carbonylation conditions by an alkynyldiol such as **1a** (formation of cyclic carbonates, maleic esters, monocyclic β- or γ-lactones, and so on) ([@bib3], [@bib20], [@bib10], [@bib47], [@bib51]). The catalytic process may be interpreted as occurring through an ordered sequence of mechanistic stages, involving (1) 5-*exo*-*dig* cyclization, via intramolecular nucleophilic attack of the hydroxyl group at C-1 to the triple bond coordinated to PdI~2~; (2) carbon monoxide insertion into the Pd-C bond of the ensuing vinylpalladium intermediate; (3) intramolecular trapping of the ensuing acylpalladium species by the hydroxyl at C-3, with further cyclization and nucleophilic displacement of palladium, leading to the final bicyclic product and Pd(0); and (4) reoxidation of Pd(0) back to PdI~2~ by oxygen in the presence of the 2 mol HI formally eliminated during the previous cyclization steps ([Scheme 1](#sch1){ref-type="fig"}; anionic iodide ligands are omitted for clarity).

We then tested the reactivity of a similar substrate, still bearing a butyl group on the triple bond, but with geminal methyl substituents at C-1. The reaction of 2,4-dimethyldec-5-yne-2,4-diol **1b** led to the corresponding dihydrofurofuranone **2b** in a higher isolated yield with respect to **2a**, most probably due to the effect exerted by the geminal alkyl groups, which is known to favor cyclization processes ([@bib16], [@bib31]). A 40% yield of **2c** was obtained starting from alkynyldiol **1c**, bearing a sterically demanding *tert*-butyl group on the triple bond. On the other hand, 2,4-dimethyl-6-phenylhex-5-yne-2,4-diol **1d**, substituted with a phenyl group on the triple bond, afforded the corresponding dihydrofuranone **2d** in 33% yield ([Scheme 2](#sch2){ref-type="fig"}).Scheme 2Formation of Dihydrofurofuranones **2a**--**d** by PdI~2~-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,3-diols **1a**--**d**Anionic iodide ligands are omitted for clarity. See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details.

A significant increase in product yield was observed when the triple bond was substituted with a trimethylsilyl group. Thus, 3-methyl-5-(trimethylsilyl)pent-4-yne-1,3-diol **1e**, under conditions similar to those previously employed for **1a**, led to the dihydrofurofuranone **2e** in 72% yield after 3 hr reaction time ([Figure 1](#fig1){ref-type="fig"}). Other differently substituted substrates **1f--m**, still bearing the trimethylsilyl group (TMS) on the triple bond, behaved similarly, and afforded the corresponding dihydrofuranones **2f--m** in fair to excellent yields (58%--94%, [Figure 1](#fig1){ref-type="fig"}). The structure of dihydrofurofuranone **2g** was also confirmed by X-ray diffractometric analysis (for details see [Figure S1](#mmc1){ref-type="supplementary-material"}, [Table S1](#mmc1){ref-type="supplementary-material"}, [Transparent Methods](#mmc1){ref-type="supplementary-material"}, and cif file for **2g**, [Data S1](#mmc2){ref-type="supplementary-material"}).Figure 1Synthesis of Dihydrofurofuranones **2** by PdI~2~/KI-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,3-diols **1**Top: *Reaction conditions:* Alkynediol **1** (0.70 mmol), PdI~2~ (1.39 × 10^−2^ mmol), KI (6.95 × 10^−2^ mmol), CO (32 atm), air (8 atm), MeOH (14 mL), 100°C, 3--15 hr. In parentheses, isolated yields based on starting **1**. See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details.Bottom: Reaction time was 3 hr for **2e**, **2f**, **2g**, **2h**, **2l**, and **2m**.Reaction time was 15 hr for **2i** and **2j**.For **2i**, the (5*RS*,6*aSR*)/(5*RS*,6*aRS*) diastereomeric ratio (DR) was ca. 1.9, determined by ^1^H NMR; starting **1i** was a mixture of (2*RS*,4*SR*)/(2*RS*,4*RS*) diastereomers (DR ca. 2.2, determined by ^1^H NMR).For **2j**, the (5*RS*,6*aSR*)/(5*RS*,6*aRS*) DR was ca. 1.8, determined by ^1^H NMR; starting **1j** was a mixture of (2*RS*,4*SR*)/(2*RS*,4*RS*) diastereomers (DR ca. 1.4, determined by ^1^H NMR).Reaction time was 5 hr for **2k**.For **2k**, the (5*RS*,6*aRS*)/(5*RS*,6*aSR*) DR was ca. 1.8, determined by ^1^H NMR; starting **1k** was a mixture of (2*RS*,4*SR*)/(2*RS*,4*RS*) diastereomers (DR ca. 1.0, determined by ^1^H NMR). See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details. NMR, nuclear magnetic resonance.

In the case of alkynediols **1i--k**, the substrates employed were a mixture of 2*RS*,4*SR* and 2*RS*,4*RS* diastereomers. To assess the different performances of the two diastereomers in the double cyclization process, we tested them independently after chromatographic separation. The reactions of the single diastereomers could also allow isolating the corresponding diastereomeric products, considering that the process is stereospecific. The results obtained are shown in [Table 1](#tbl1){ref-type="table"}. As can be seen from [Table 1](#tbl1){ref-type="table"}, the 2*RS*,4*RS* diastereomer was the most productive isomer (in terms of yield obtained for the corresponding dihydrofurofuranone) in the case of **1i** and especially **1k**, whereas in the case of **1j** a slightly higher yield was observed starting from the 2*RS*,4*SR* diastereoisomer. The structure of (5*RS*,6*aRS*)-**2j** was unequivocally established by X-ray diffractometric analysis (for details, see [Figure S2](#mmc1){ref-type="supplementary-material"}, [Table S2](#mmc1){ref-type="supplementary-material"}, [Transparent Methods](#mmc1){ref-type="supplementary-material"}, and cif file for 5*RS*,6*aRS*-**2j**, [Data S2](#mmc3){ref-type="supplementary-material"}), which also permitted to corroborate (owing to the stereospecificity of the reaction) the 2*RS*,4*RS* stereochemistry of the starting material **1j**.Table 1Experiments with Single DiastereomersEntry[a](#tblfn1){ref-type="table-fn"}**1**Time (h)**2**Yield of **2**[b](#tblfn2){ref-type="table-fn"}1(2*RS*,4*SR*)-**1i**8(5*RS*,6*aSR*)-**2i**522(2*RS*,4*RS*)-**1i**3(5*RS*,6*aRS*)-**2i**613(2*RS*,4*SR*)-**1j**15(5*RS*,6*aSR*)-**2j**684(2*RS*,4*RS*)-**1j**8(5*RS*,6*aRS*)-**2j**525(2*RS*,4*SR*)-**1k**5(5*RS*,6*aSR*)-**2k**406(2*RS*,4*RS*)-**1k**3(5*RS*,6*aRS*)-**2k**80[^3][^4]

To further expand the synthetic scope of the reaction, we also attempted the desilylation of some representative silylated dihydrofurofuranones. Thus, crude products **2h**, **2l**, and **2m**, deriving from carbonylation of **1h**, **1l**, and **1m**, respectively, were treated, without further purification, with tetrabutylammonium fluoride (TBAF)۰*n*H~2~O in THF at room temperature for 2 hr. As shown in [Scheme 3](#sch3){ref-type="fig"}, the corresponding desilylated furofuranone derivatives were obtained in good to high yields over the two steps (85%, 79%, and 61% based on starting **1h**, **1l**, and **1m**, respectively).Scheme 3Synthesis of Desilylated Dihydrofurofuranones **3h**, **3l**, and **3m** by PdI~2~-Catalyzed Carbonylative Double Cyclization of 4-Yne-1,3-diols **1h**, **1l**, and **1m**, Respectively, Followed by TBAF-Induced Desilylation of the Crude Carbonylation ProductSee [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details.

Antiproliferative Activity *In Vitro* of the Newly Synthesized Dihydrofurofuranones on MCF-7, MDA-MB-231, and MDA-MB-468 Human Breast Cancer Cell Lines {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Some of the newly synthesized dihydrofurofuranones have shown significant antiproliferative activity *in vitro* on human breast adenocarcinoma cell lines, including the most dangerous triple-negative ones (MDA-MB-231 and MDAMB-468). Although several furanone derivatives were previously described to possess antitumor properties (for a recent example, see [@bib52]), the possible anticancer activity of bicyclic dihydrofurofuranones such as **2** has not been reported so far. The effects on tumor cell viability of different concentrations (1, 5, 10, 20, 40 μM) of five 6,6*a*-diidrofuro\[3,2-*b*\]furan-2-(5*H*) derivatives (**2d**, **2e**, **2g**, **2l**, and **3l**) have been evaluated against MCF-7, MDAMB-231, and MDAMB-468 BC cell lines ([Figure 2](#fig2){ref-type="fig"}); normal breast epithelial cells MCF-10A; and immortalized fibroblasts 3T3-L1 ([Figure 3](#fig3){ref-type="fig"}). In particular, for **2d** a significant reduction in vitality of MCF-7 and MDA-MB231 was observed from 10 μM onward, whereas MDA-MB468 was slightly more sensitive and a significant reduction was obtained from the dose of 5 μM ([Figure 2](#fig2){ref-type="fig"}A). Compound **2g** decreased the cell viability of all three cell lines from the lowest dose of 1 μM ([Figure 2](#fig2){ref-type="fig"}B). Compound **2e** significantly affected the cell viability of TNBC cell lines from 5 μM, whereas it was effective from 10 μM on MCF-7 cells ([Figure 2](#fig2){ref-type="fig"}C). Product **2l** also decreased MCF-7 (1--40 μM), MDA-MB-231, and MDA-MB-468 (10--40 μM) cell viability ([Figure 2](#fig2){ref-type="fig"}D). Dihydrofurofuranone **3l** caused a modest but significant effect on MCF-7 (5--40 μM) and MDA-MB-231 (20--40 μM) cells, and was slightly more effective on MDA-MB-468, with the highest dose (40 μM) reaching almost a 40% inhibition ([Figure 2](#fig2){ref-type="fig"}E). These data indicate that among all tested cell lines MDA-MD-468 appears more sensitive to all compounds. This event could rely on a different pattern of gene expression present in these cells. A clear definition of target genes will help to explain such a difference.Figure 2Dihydrofurofuranones **2d**, **2e**, **2g**, **2l**, and **3l** Decrease Breast Cancer Cell Viability(A--E) MCF-7, MDA-MB-231 and MDA-MB-468 cells were left untreated (0) or treated with different doses (1--40 μM) of **2d** (A), **2g** (B), **2e** (C), **2l** (D), and **3l** (E) for 72 hr. Cell viability was evaluated by MTT (MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Results were expressed as mean ± SD of three independent experiments each performed in triplicate. Statistically significant differences are indicated (\*p \< 0.05 versus basal). See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details. SD, standard deviation.Figure 3Effects of Dihydrofurofuranones **2d**, **2e**, **2g**, **2l**, and **3l** on MCF-10A and 3T3-L1 Cell Viability(A--E) MCF-10A and 3T3-L1 cells were left untreated (0) or treated with different doses (1--40 μM) of **2d** (A), **2g** (B), **2e** (C), **2l** (D), and **3l** (E) for 72 hr. Cell viability was evaluated by MTT ( 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay. Results were expressed as mean ± SD of three independent experiments each performed in triplicate. Statistically significant differences are indicated (\*p \< 0.05 versus basal). See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details. SD, standard deviation.

To exclude the toxic effects of these compounds, experiments using normal breast epithelial cells MCF-10A and immortalized fibroblasts 3T3-L1 have been performed. As shown in [Figure 3](#fig3){ref-type="fig"}, the proliferative behavior of these cells is not affected by all doses of **2l** ([Figure 3](#fig3){ref-type="fig"}D) and **3l** ([Figure 3](#fig3){ref-type="fig"}E), whereas **2d** ([Figure 3](#fig3){ref-type="fig"}A), **2g** ([Figure 3](#fig3){ref-type="fig"}B), and **2e** ([Figure 3](#fig3){ref-type="fig"}C) caused a reduction of cell viability in both MCF-10A and 3T3-L1 cells. In particular, in MCF-10A cells, **2d** exerted a slight but statistically significant inhibitory effect at 20 and 40 μM ([Figure 3](#fig3){ref-type="fig"}A), whereas **2g** was effective starting from 5 μM ([Figure 3](#fig3){ref-type="fig"}B) and **2e** starting from 10 μM ([Figure 3](#fig3){ref-type="fig"}C). Moreover, in 3T3-L1, **2d** ([Figure 3](#fig3){ref-type="fig"}A) and **2e** ([Figure 3](#fig3){ref-type="fig"}C) decreased viability at 40 μM, whereas **2g** ([Figure 3](#fig3){ref-type="fig"}B) was effective from 20 μM.

Taken together, the results obtained indicate that, among all compounds, 5,5-dimethyl-6*a*-phenyl-3-(trimethylsilyl)-6,6*a*-dihydrofuro\[3,2-*b*\]furan-2(5*H*)-one **2l** is the one with the most significant inhibitory effects on the cell vitality of tumor cells, whereas it has little or no effect on the vitality of normal cells. This prompted us to investigate the molecular mechanism behind the **2l**-dependent decrease of BC cell viability. To this aim, we performed assays aimed to investigate if **2l** initiated an apoptotic mechanism in MCF-7 and MDA-MB-231 and MDA-MB-468 cells. Apoptosis is an energy-dependent process characterized by a number of hallmarks, such as membrane blebbing, nuclear chromatin condensation, cell shrinkage, internucleosomal DNA fragmentation, and protein cleavage ([@bib4]). During apoptosis enzymes with cysteine protease activity designed as "caspases" ([@bib6]) cleave several substrates including parp-1, a DNA nick sensor that catalyzes DNA repair ([@bib8], [@bib35]). After cleavage, parp-1 loses the nick sensor function and is inactive toward DNA damage. Using western blot analysis, we showed that **2l** treatment induced parp-1 cleavage in all three cell lines ([Figures 4](#fig4){ref-type="fig"}A--4C).Figure 4Treatment with Dihydrofurofuranone **2l** Induces parp-1 Cleavage in Breast Cancer Cells(A--C) Cells were left untreated (-) or treated with **2l** (20 μM) (+) for 48 hr. Western blot analyses of parp-1 in MCF-7 (A), MDA-MB-231 (B), and MDA-MB-468 (C) were performed on equal amounts of total proteins. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details.

In addition, we also investigated the effect of **2l** on the activation of other apoptotic markers, in particular the bcl-2 family members, playing pivotal roles in regulating the mitochondrial apoptotic pathway. As can be seen from [Figure 5](#fig5){ref-type="fig"}, the presence of **2l** decreased bcl-2 expression ([Figure 5](#fig5){ref-type="fig"}A) in all three BC cell lines. Cytosolic translocation of cytochrome *c* has been proposed to be an essential step in the mitochondria-dependent apoptotic pathway. In fact, cytochrome *c* release from mitochondria into the cytosol triggers caspase activation ([@bib22], [@bib44], [@bib45]). Therefore, we examined if cytochrome *c* was released into the cytosol after treatment with **2l**. Cytosolic protein fraction was isolated and analyzed by western blot analysis ([Figure 5](#fig5){ref-type="fig"}B). As reported in [Figure 5](#fig5){ref-type="fig"}B, cytochrome *c* levels increased in the cytosolic fraction of all three BC cell lines treated with **2l**.Figure 5Treatment with Dihydrofurofuranone **2l** Modulates the Expression of Apoptotic Markers in Breast Cancer Cells(A and B) MCF-7, MDA-MB-231, and MDA-MB-468 breast cancer cells were left untreated (bs, −) or treated with **2l** (20 μM) (**2l**, +) for 48 hr. Western blot analyses of bcl-2 (A) and cytochrome *c* (cyt c) (B) were performed on equal amounts of total proteins. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. (A and B, upper panels) Graphs represent means of normalized optical densities from three experiments, bars represent SD (\*p \< 0.05 versus untreated cells \[−\]). See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details. SD, standard deviation.

Conclusions {#sec2.3}
-----------

In conclusion, we have reported a novel carbonylative double cyclization approach to biologically active 6,6*a*-dihydrofuro\[3,2-*b*\]furan-2(5*H*)-ones **2** starting from simple and readily available starting materials (4-yne-1,3-diols **1**, carbon monoxide, and oxygen). The process allows the formation of two cycles and three new bonds (O-C, C-C, and C-O) in one single operation and in ordered sequence. The dihydrofurofuranones thus synthesized have shown a significant antitumor activity against BC cell lines. In particular, 5,5-dimethyl-6*a*-phenyl-3-(trimethylsilyl)-6,6*a*-dihydrofuro\[3,2-*b*\]furan-2(5*H*)-one **2l** showed the most significant inhibitory effects on the cell vitality of tumor cells, whereas it had practically no effect on the vitality of normal cells. For **2l**, molecular events leading to cell death were further investigated, and the results evidenced that this molecule was able to activate an intrinsic apoptotic mechanism.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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